IPAs Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai VICTORIA, British Columbia - ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), a leading AI-driven biotherapeutic research and technology company, is proud to announce a significant collaboration between its subsidiary, BioStrand, and PGxAI. This strategic partnership aims to revolutionize the precision medicine field of pharmacogenomics by harnessing the power of BioStrand’s groundbreaking technology - the patented Foundation AI Model, LENSai.
Pharmacogenomics is an emerging field that studies how individual genetic variations can impact an individual’s response to medication. By combining the genetic information of a patient with their electronic medical records, pharmacogenomics experts can identify genetic markers that may help predict an individual’s response to specific drugs. This personalized approach enables healthcare providers to optimize treatments and minimize adverse reactions, ultimately improving patient outcomes.
LENSai, developed by BioStrand, is an advanced artificial intelligence model that utilizes machine learning algorithms to analyze vast amounts of genomic data and extract meaningful insights. Its unique capabilities allow it to identify genetic markers associated with drug sensitivity, efficacy, and toxicity. This collaboration between BioStrand and PGxAI aims to leverage LENSai’s powerful capabilities to develop a first-in-class AI model specifically designed for pharmacogenomics recommendations.
The partnership between BioStrand and PGxAI signifies a major step forward in advancing precision medicine. By combining BioStrand’s expertise in AI-driven biotherapeutic research and technology with PGxAI’s domain knowledge in pharmacogenomics, this collaboration promises to offer healthcare providers a groundbreaking solution for personalized and evidence-based treatment recommendations.
Moreover, this collaboration supports the commercial rollout of LENSai’s Application Programming Interface (API) by expanding LENSai’s feature set. The expanded capabilities of LENSai’s API will enable healthcare providers to seamlessly integrate LENSai’s recommendations into their existing electronic medical record systems, further streamlining the adoption and implementation of precision medicine practices.
Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies and BioStrand, expressed her excitement about the collaboration, stating, We are thrilled to work with PGxAI to unlock the full potential of pharmacogenomics through the power of artificial intelligence. By combining our proprietary LENSai technology with PGxAI’s domain expertise, we aim to create a first-in-class AI model that will revolutionize the field and improve patient care.
In summary, the strategic collaboration between BioStrand and PGxAI holds immense promise for advancing precision medicine by harnessing the power of artificial intelligence. By developing a first-in-class AI model for pharmacogenomics recommendations using LENSai, this collaboration will ultimately benefit patients by providing personalized and optimized treatment options. With the commercial rollout of LENSai’s API, healthcare providers can seamlessly integrate this groundbreaking technology into their practice, paving the way for a new era of precision medicine.
Comments